The Role of Helicobacter pylori in Laryngopharyngeal Reflux.
Objective The primary objective was to determine the prevalence of Helicobacter pylori among patients with laryngopharyngeal reflux. The secondary objective was determining if H pylori eradication leads to greater symptom improvement in patients with laryngopharyngeal reflux as compared with standard proton pump inhibitor therapy alone. Data Sources EMBASE, Cumulative Index to Nursing and Allied Health Literature, MEDLINE, World Health Organization International Clinical Trials Registry Platform, European Union Clinical Trials Register, Cochrane Library databases of clinical trials, and ClinicalTrials.gov. Review Methods A systematic review was performed of studies assessing the diagnosis or treatment of H pylori among patients with laryngopharyngeal reflux. Randomized controlled trials, cohort studies, case-control studies, and case series were included. A meta-analysis of prevalence data and assessment of heterogeneity was performed on relevant studies. Results Fourteen studies were analyzed in the review, with 13 eligible for the meta-analysis. We determined that the prevalence of H pylori among patients with laryngopharyngeal reflux was 43.9% (95% confidence interval, 32.1-56.5). The heterogeneity of studies was high, with an overall I2value of 92.3%. We were unable to quantitatively assess findings for our secondary outcome, since H pylori identification and treatment were not the primary focus of the majority of studies. Conclusion There is a high rate of H pylori infection among patients with laryngopharyngeal reflux. The infection rate in North America and Western Europe has not been adequately studied. There is insufficient evidence to make a recommendation regarding the testing and treatment of H pylori infection among patients with laryngopharyngeal reflux.
1 Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, Ottawa, Canada.
Ross
R
Campbell
1 Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, Ottawa, Canada.
Shaun J
SJ
Kilty
2 Knowledge Synthesis Group, Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, Canada.|3 Public Health and Preventive Medicine, School of Epidemiology, University of Ottawa, Ottawa, Canada.
Brian
B
Hutton
1 Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, Ottawa, Canada.
James P
JP
Bonaparte
D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D016480:Helicobacter pylori; D006801:Humans; D057045:Laryngopharyngeal Reflux / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology*; D015995:Prevalence; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*
D054328:Proton Pump Inhibitors
H pylori; Helicobacter pylori; LPR; extraesophageal gastroesophageal reflux disease; laryngopharyngeal reflux; reflux laryngitis